This Is A Custom Widget

This Sliding Bar can be switched on or off in theme options, and can take any widget you throw at it or even fill it with your custom HTML Code. Its perfect for grabbing the attention of your viewers. Choose between 1, 2, 3 or 4 columns, set the background color, widget divider color, activate transparency, a top border or fully disable it on desktop and mobile.

This Is A Custom Widget

This Sliding Bar can be switched on or off in theme options, and can take any widget you throw at it or even fill it with your custom HTML Code. Its perfect for grabbing the attention of your viewers. Choose between 1, 2, 3 or 4 columns, set the background color, widget divider color, activate transparency, a top border or fully disable it on desktop and mobile.

inner_image_1920x170

RESEARCH & DEVELOPMENT

Publications

By |February 28th, 2016|Research & Developement|

Ablin M. Entin-Meer V. Aloush S. et al. Protective effect of eotaxin-2 inhibition in adjuvant-induced arthritis. Clinical and Experimental Immunology. 2010; V161(2):276–83. Mausner-Fainberg K, Karni A, George J, et al. Eotaxin-2 blockade ameliorates experimental autoimmune encephalomyelitis. World J. Immunol. 2013 Mar; 3(1):7-14. Mor A, Afek A, Entin-Meer M, Keren G, George J. Anti eotaxin-2 antibodies [...]

Comments Off on Publications

Indications

By |February 28th, 2016|Research & Developement|

Nonalcoholic steatohepatitis (NASH) Nonalcoholic steatohepatitis or NASH is a common liver disease. It resembles alcoholic liver disease but occurs in people who drink little or no alcohol. The pathophysiology involves fat accumulation (steatosis), inflammation, and, variably, fibrosis. Steatosis results from hepatic triglyceride accumulation. Most patients are asymptomatic. However, some have fatigue, malaise, or right upper [...]

Comments Off on Indications

Lead Product

By |February 28th, 2016|Research & Developement|

CM101 is a first in class monoclonal antibody directed against a novel target found to be involved in inflammatory and fibrotic processes. CM-101 has completed seven years of various pre-clinical testing in-vitro, ex-vivo and in-vivo in several animal models.  CM101 has been shown to be beneficial in multiple experimental models of NASH, PSC and systemic [...]

Comments Off on Lead Product

Scientific Overview

By |February 28th, 2016|Research & Developement|

ChemomAb identified a novel chemokine pathway that mediates inflammation and fibrosis and subsequently developed proprietary antibodies that target it.  Compelling data has been gathered on the efficacy of ChemomAb’s lead compound in models of nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC)  and systemic sclerosis. CM-101 is the lead monoclonal anti-chemokine antibody that binds  a unique [...]

Comments Off on Scientific Overview